Skip to main content

Table 1 Characteristics of patients according to the 2015 ATA risk-stratification system in the postoperative setting

From: Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome

  LR
(n = 395)
IR
(n = 202)
HR
(n = 21)
p
Mean age ± SD (yrs) 49 ± 15 51 ± 18 67 ± 10 <.0001
Sex ratio (Female) 3.8 (79%) 2.0 (67%) 2.5 (71%) 0.005
Mean tumor size ± SD (mm) 22 ± 15 25 ± 18 51 ± 34 <.0001
Histology   
 PTC 348 (88%) 169 (84%) 11 (52%) <.0001
 FTC 47 (12%) 12 (6%) 4 (19%)  
 PDTC 0 21 (10%) 6 (29%)  
Aggressive pathological subtypes   <.001
 No 395 (100%) 172 (85%) 18 (86%)  
 Yes 0 30 (15%) 3 (14%)  
Extra-thyroidal extension   <.0001
 Minimal 0 91 (45%) 1 (5%)  
 Gross 0 0 14 (67%)  
T status (TNM 2017)   <.0001
 T1a + T1b 230 (58%) 112 (56%) 1 (5%)  
 T2 152 (39%) 57 (28%) 4 (19%)  
 T3a + T3b 13 (3%) 33 (16%) 2 (9%)  
 T4a + T4b 0 0 14 (67%)  
N status (TNM 2017)   <.0001
 Nx 249 (63%) 31 (15%) 6 (28%)  
 N0 119 (30%) 27 (13%) 5 (24%)  
 N1a + N1b 27 (7%) 144 (72%) 10 (48%)  
M status (TNM 2017)   <.0001
 M0 395 (100%) 202 (100%) 10 (48%)  
 M1 0 0 11 (52%)  
Positive TgAb level 48 (12%) 32 (16%) 2 (10%) 0.43
Stimulated Tg level at RAI treatment (range)a 1.9 (0.1–744.0) 6.4 (0.1–4340.0) 126.2 (0.4–58,690.0) <.0001
  1. aIn patients without positive TgAb level